The study found that 97 per cent of patients in the rapid-initiation group (dubbed the RapIT intervention) had started antiretroviral therapy (ART) within 90 days, compared to 72 per cent receiving standard care.
By 10 months of enrolment, 64 per cent of patients in the rapid group had good outcomes, in terms of viral suppression, compared to 51 per cent in the standard arm.
Once they get to a clinic, the treatment initiation process is long and complicated, Rosen said, with a first visit for an HIV test, a second visit to determine treatment eligibility, and several more visits for a physical exam, adherence education and counselling.
The researchers hypothesised that offering patients a chance to start treatment on the same day as their first clinic visit would improve the proportion of patients who made it through all the steps and underwent ART.
One was offered the chance to start treatment on the same day, using rapid lab tests, accelerated counselling and a physical exam, and the other was assigned to standard treatment procedures, usually requiring three to five more clinic visits over a two- to four-week period.
"The RapIT intervention showed clinically meaningful improvements in ART uptake and viral suppression, providing proof of principle that a single-visit treatment approach can have benefits," Rosen said.
"The patients who likely benefited the most from it are those who would not otherwise have initiated treatment at all, or who would have waited until they were sick enough to compromise their prognosis," she said.
However, so many more patients in the standard group failed to start treatment at all - 28 per cent, compared to the rapid group's three percent - that patients in the rapid group still had overall better outcomes than did those in the standard group.
While the rapid intervention was successful in increasing the overall proportion of patients with successful health outcomes, "the rate of post-initiation attrition is a reminder that early retention in care and adherence support, once patients start treatment, remain high priorities for further research and interventions."
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
